Which organizations are lobbying on the active drug pricing bills in the 119th Congress, and what coalition or side is each on?
Drug pricing legislation in the 119th Congress has attracted significant lobbying activity, with clear coalitions forming around price-control approaches. Here's the breakdown:
Pro-Price-Control Coalition
Organizations supporting aggressive drug pricing measures:
- Public Citizen - $99,800 in lobbying (2025 Q3) supporting S. 1753 End Price Gouging for Medications Act
- Drug Policy Alliance - $56,366 in lobbying (2025 Q1-Q3) supporting price-control and drug-access bills
- Port Side Strategies (representing Coalition to Protect America's National Parks) - $40,000 in lobbying supporting S. 1753 and S. 1836 SMART Prices Act
- T1International USA - Patient advocacy organization lobbying on multiple pricing bills including S. 1818 Prescription Drug Price Relief Act and S. 1587 Fair Prescription Drug Prices for Americans Act
Anti-Price-Control Coalition
Organizations opposing price controls and international reference pricing:
- America's Health Insurance Plans (AHIP) - $20,730,000 in disclosed lobbying expenses (2025 Q2-Q3, 2026 Q1-Q2) actively opposing price-control bills across S. 1818, S. 1587, H.R. 3375, H.R. 3546, and S. 1753
- Healthcare Institute of New Jersey - $98,643 in lobbying explicitly opposing "the imposition of price controls in the Medicare Part D program" and "international price index" efforts
- Grifols Shared Services North America - $2,160,000 in lobbying (specialty medicines manufacturer) opposing price-control provisions
- Biotechnology Innovation Organization - $1,840,000 in lobbying opposing drug pricing restrictions
Key Takeaway
AHIP's $20.7 million in disclosed lobbying dwarfs pro-pricing advocacy by a factor of 200+, making the insurance industry the dominant lobbying force against price controls. The pro-pricing coalition consists primarily of patient advocacy groups and consumer organizations with far smaller budgets.
Sources
Sources
- S. 1818 § 2 - Prescription Drug Price Relief Act of 2025 (Congress.gov)
- S. 1587 (b) - Fair Prescription Drug Prices for Americans Act (Congress.gov)
- H.R. 3375 (b) - Fair Prescription Drug Prices for Americans Act (Congress.gov)
- H.R. 3546 § 2 - Prescription Drug Price Relief Act of 2025 (Congress.gov)
- H.R. 9040 § 2 - Regulate the Price of All Drugs Act (Congress.gov)
- H.R. 6166 § 102 - Lowering Drug Costs for American Families Act (Congress.gov)
- H.R. 3391 § 1 - End Price Gouging for Medications Act (Congress.gov)
- S. 1753 § 1 - End Price Gouging for Medications Act (Congress.gov)
- H. Res. 928 (A) - (B) - Affirming support for most-favored-Nation drug pricing for United States patients. (Congress.gov)
- H.R. 3493 § 1 - Global Fairness in Drug Pricing Act (Congress.gov)
- S. 229 § 2 - DTC Act of 2025 (Congress.gov)
- H.R. 3789 § 2 - DTC Act of 2025 (Congress.gov)
- S. 2617 § 1 - Reducing Drug Prices for Seniors Act. (Congress.gov)
- S. 1506 (C) - Medicare for All Act (Congress.gov)
- H.R. 9699 (A) - Drug Deal Disclosure Act (Congress.gov)
- Lobbying Activity — s-1818-119 (Senate LDA)
- Lobbying Activity — s-1587-119 (Senate LDA)
- Lobbying Activity — hr-3375-119 (Senate LDA)
- Lobbying Activity — hr-3546-119 (Senate LDA)
- Lobbying Activity — hr-3391-119 (Senate LDA)